Abstract Library

#3036 Can Ki-67 with 5.5% Be Better in Predicting Prognosis for Well Differentiated Pancreatic Neuroendocrine Tumors?

Introduction: Pancreatic neuroendocrine tumors (NETs) are rare malignancies, Ki-67 is a cell proliferation marker that has been shown to have some utility in predicting prognosis of neuroendocrine tumors. However, the ideal grading method for G1/G2 remains controversial.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Tan H

Authors: Yuan B, Chen Y, Zhang P, Wang X, Tan H,

Keywords: Pancreatic net, G1, G2, Ki-67, overall survival time,

#2949 Sunitinib May Be an Effective Treatment for Hypercalcemia Due To a Metastatic Pancreatic Neuroendocrine Tumor

Introduction: Malignant hypercalcemia due to neuroendocrine tumor(NET) is rare, and only a few reports are available in the literature.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Wang C

Authors: Wang C, Qi Z, Tan H, Tan H,

Keywords: hypercalcemia, pancreatic NET, sunitinib,

#2948 Efficacy Prediction Using Computed Tomography for Patients with Pancreatic Neuroendocrine Tumors Receiving Sunitinib

Introduction: How to predict the efficacy of sunitinib before treatment initiation was less known.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Zhang Y, Chen L, Wang W, Jin K, Yuan B,

Keywords: sunitinib, computed tomography, efficacy prediction,

#2946 Analysis of Factors Related to Gallstones in Patients with Neuroendocrine Tumors Treated with Long-Acting Somatostatin Analogues

Introduction: Somatostatin analogs are the backbone of neuroendocrine neoplasms treatment. Biliary stone disease is a potentially severe adverse event of somatostatin analogs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Qi Z, Zhang Y, Li Y, Shi y, Wang x,

Keywords: neuroendocrine neoplasms, somatostatin analogs, gallstone,

#2853 Succinate Dehydrogenase B (SDHB) Immunohistochemical Expression in Pancreatic Neuroendocrine Tumours and Correlation with Somatostatin Receptor Immunohistochemistry

Introduction: The established category of succinate dehydrogenase (SDH) deficient neoplasms includes several endocrine tumours with recent evidence that pancreatic neuroendocrine tumours (PNETs) could be included in this tumour group. The SDH complex is composed of four subunits (A-D) but loss of immunohistochemical (IHC) expression for SDHB indicates bi-allelic inactivation of any SDH component and is used as a marker for syndromic disease.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Swan N

Authors: Swan N, Nadeem N, Crowley R,

Keywords: succinate dehydrogenase, pancreatic neuroendocrine tumor, somatostatin receptor, immunohistochemistry,